Eli Lilly just posted its strongest quarter on record, with second-quarter revenue of $23 billion, up 48% year over year, and the company raised full-year guidance to a range of $85 billion to $87 billion. The growth engine behind that number is largely GLP-1 weight loss and diabetes treatments, a category that's reshaped the entire pharmaceutical sector's growth profile over the past two years. Foundayo, Lilly's GLP-1 pill approved by the FDA back in April, has added a new format to that franchise on top of its existing injectable treatments.

That kind of growth at that scale from a single company is unusual for an industry that has historically grown in the mid-single digits. It's also concentrated risk. A meaningful share of the sector's recent strength traces back to demand for one drug class, at one company, which makes Lilly's execution on manufacturing capacity and continued clinical differentiation more consequential to the broader healthcare sector's performance than a single company's earnings would normally be.

The merger rumor nobody's confirming

Adding to the sector's momentum, unconfirmed reports have floated a roughly $400 billion combination between two major pharmaceutical companies that, if real, would create the world's largest drugmaker by revenue. A senior source denied the talks, and analysts remain genuinely split on whether any negotiation happened at all. Regardless of whether this specific deal materializes, the fact that a rumor at this scale gained traction says something about where investor appetite currently sits: primed for consolidation in a sector where scale increasingly determines who can fund the R&D pipeline needed to compete in categories like GLP-1s.

The rest of the sector is moving too, just more quietly

Johnson & Johnson raised its full-year revenue guidance to $100.3 billion to $101.3 billion and lifted its quarterly dividend to $1.34 per share, marking 64 consecutive years of dividend increases. That kind of multi-decade consistency is a different investment case entirely from Lilly's growth story, offering steady, defensive income rather than explosive upside tied to a single drug category.

Merck, meanwhile, closed its $6.7 billion acquisition of Terns Pharmaceuticals in May, a deal aimed squarely at bolstering its oncology pipeline. That's the more traditional playbook in pharma: buy smaller, clinical-stage biotechs with promising late-stage data rather than build every capability internally, and it's a pattern likely to continue as larger players look to diversify beyond whichever single category is currently driving headlines.

This kind of bolt-on acquisition strategy also serves as a hedge against exactly the concentration risk sitting underneath Lilly's numbers. A company with a diversified pipeline across oncology, immunology, and other therapeutic areas isn't as exposed if growth in any single category, including GLP-1s, eventually slows as the market matures and competition intensifies.

Whitmore's Watchlist:
LLY(Eli Lilly and Company): The clearest direct play on the GLP-1 growth story currently reshaping the sector's overall growth profile.
JNJ(Johnson & Johnson): A diversified, dividend-focused alternative to the concentrated growth bets elsewhere in pharma.
MRK(Merck & Co.): Positioned through recent M&A to diversify its pipeline beyond any single therapeutic category.

Why "undervalued" keeps showing up in sector commentary

Analysts have flagged healthcare broadly as an undervalued entry point heading into the second half of the year, a somewhat unusual label for a sector containing a company growing revenue 48% year over year. That disconnect reflects how much of the broader healthcare index has lagged even as GLP-1 names have soared, since large defensive names without direct exposure to that specific growth category haven't rerated alongside the leaders.

That gap is worth watching closely rather than assuming it closes automatically. A sector-wide "healthcare is cheap" thesis only plays out if the laggards actually catch up on fundamentals, not simply on sentiment, and dividend-focused names like JNJ are a genuinely different bet than growth-driven ones like Lilly even when both get grouped under the same sector label.

Investors weighing broad healthcare exposure right now are effectively choosing between two different theses at once: a bet that GLP-1 growth keeps compounding at anything close to its current pace, and a separate bet that the sector's laggards eventually rerate as valuations catch analysts' attention. Those aren't the same trade, and conflating them is an easy way to misjudge what a given fund or stock is actually offering.

Whitmore's Take: Pharma's recent strength is real, but it's heavily concentrated in one drug category at one company, with the rest of the sector telling a much quieter story. Worth knowing which kind of pharma exposure, growth-driven or defensive, any current healthcare position is actually capturing.

Written by Daniel Whitmore
Millionaire Insiders